EQUILLIUM, INC. (EQ) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.48M USD | Liabilities, Current |
| Cash and equivalents | 57.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.48M | $57.16M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $3.35M | $61.32M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.93M | $30.28M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $3.09M | $33.12M | $0.00 | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.23M | $11.49M | $0.00 | (m) | (m) | (m) |
| 2025-03-31 | (m) | $6.00M | $14.50M | $0.00 | (m) | (m) | (m) |
| 2024-12-31 | $22.57M | $6.36M | $18.09M | $4.49M | $0.00 | (m) | 3.55× |
| 2024-09-30 | $30.89M | $11.06M | $15.45M | $10.43M | $5.01M | (m) | 2.79× |
| 2024-06-30 | $39.19M | $20.17M | $11.06M | $22.24M | $5.89M | (m) | 1.94× |
| 2024-03-31 | $37.33M | $22.21M | $11.57M | $20.72M | $5.05M | (m) | 1.68× |
| 2023-12-31 | $44.60M | $27.57M | $23.22M | $17.65M | $3.73M | (m) | 1.62× |
| 2023-09-30 | $50.08M | $28.20M | $34.38M | $11.92M | $3.77M | (m) | 1.78× |
| 2023-06-30 | $52.12M | $25.22M | $25.62M | $22.75M | $3.74M | (m) | 2.07× |
| 2023-03-31 | $65.42M | $32.02M | $24.50M | $37.49M | $3.42M | (m) | 2.04× |
| 2022-12-31 | $73.86M | $32.04M | $59.11M | $11.92M | $2.84M | (m) | 2.31× |
| 2022-09-30 | (m) | $14.93M | $25.73M | $18.79M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $15.19M | $23.81M | $33.75M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $13.11M | $26.24M | $42.58M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $8.91M | $50.37M | $30.34M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $7.78M | $77.16M | $13.54M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.98M | $73.53M | $24.12M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $7.42M | $50.86M | $53.22M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $7.25M | $23.98M | $58.18M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $5.14M | $49.25M | $41.29M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.39M | $24.08M | $18.52M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.71M | $20.61M | $27.06M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.88M | $13.22M | $39.92M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $4.27M | $27.66M | $34.58M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $3.66M | $22.66M | $34.28M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.05M | $21.39M | $40.21M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.03M | $28.51M | $37.40M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.68M | $4.98M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $568.82K | $7.10M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |